Ziresovir in the treatment of RSV

Ziresovir

• is a potent, selective, and orally bioavailable Respiratory syncytial virus (RSV) F protein inhibitor
  • RSV is a member of the species Human orthopneumovirus and belongs to the Pneumoviridae genus of the family Pneumoviridae, order Mononegavirales
    • the 15.2 kb non-segmented genome contains 10 mRNA species encoding 11 distinct proteins, including three surface glycoproteins (SH, G, and F) and several proteins (N, P, L, and M2-1) that comprise the viral RNA-dependent RNA polymerase complex (RdRp)
      • the RSV F protein is the class I viral trimeric fusion (F) glycoprotein, which mediates RSV entry in response to binding of the attachment (G) glycoprotein to a host receptor
      • F protein is critical for the fusion of the viral membrane with the cell plasma membrane, leading to infection of the host cells

Study evidence showed that ziresovir treatment reduced signs and symptoms of bronchiolitis in infants and young children hospitalized with RSV infection (2).

Reference:

1. Huang LM et al. Safety and efficacy of AK0529 in respiratory syncytial virus-infected infant patients: A phase 2 proof-of-concept trial. Influenza Other Respir Viruses. 2023 Jul 25;17(7):e13176.
2. Zhao S et al. Ziresovir in Hospitalized Infants with Respiratory Syncytial Virus Infection. NEJM 2024;391:1096-1107.